1. Canada Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
INTELLIPHARMACEUTICS INTL INC

INTELLIPHARMACEUTICS INTL INC

OOTC:IPCIQ
0.00
USD
0.00
(0.00%)
-0.09EPS
2.61MMarket Cap
INTELLIPHARMACEUTICS INTL INC
OTC:IPCIQ
(OTC Markets)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
USD
- -
- -
- -
0.13
0.03
0.01
0.08
0.38
0.17
0.08
0.18
0.36
0.16
0.06
- -
- -
0.03
Revenue per Share
-1.46
-0.58
- -
-0.53
-0.33
-0.36
-0.58
-0.17
-0.31
-0.38
-0.29
-2.89
-0.37
-0.14
-0.17
-0.09
-0.1
Basic EPS, GAAP
-1.31
-0.55
- -
-0.58
-0.48
-0.5
-0.36
-0.11
-0.18
-0.25
-0.26
-2.65
-0.31
- -
-0.08
-0.04
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
10.43
2.91
4.25
0.09
-1.94
-0.99
-2.78
2.09
-0.06
0.37
0.11
0.22
-0.17
-0.27
-0.25
-0.32
-0.39
Book Value per Share
10.43
2.91
4.25
0.09
-1.94
-0.99
-2.78
2.09
-0.06
0.37
0.11
0.22
-0.17
-0.27
-0.25
-0.32
-0.39
Tangible Book Value per Share
20
22
1
11
15
17
20
23
24
27
31
5
22
24
29
33
33
Basic Weighted Avg Shares
- -
- -
- -
1
1
- -
2
9
4
2
6
2
3
1
- -
- -
1
Sales/Revenue/Turnover
- -
- -
- -
-412.22
-1,549.72
-9,347.14
-446.4
-40.28
-173.76
-438.41
-150.17
-778.07
-225.11
-333.8
- -
-4,336.82
-279.57
Operating Margin (%)
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
- -
- -
- -
Depreciation Expense
-29
-13
- -
-6
-5
-6
-11
-4
-7
-10
-9
-14
-8
-3
-5
-3
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-394.76
-972.53
-5,730.51
-752.55
-43.97
-181.65
-451.43
-160.91
-802.66
-232.28
-241.95
- -
-4,400.55
-350.72
Profit Margin (%)
23
7
5
-1
3
-1
-2
3
-2
2
-1
3
-6
-8
-9
-12
-14
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
23
7
5
- -
-3
-2
-6
5
- -
1
- -
4
-4
-6
-8
-11
-13
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-128.18
-86.67
- -
-243.86
- -
- -
- -
- -
- -
- -
-1,178.91
-612.54
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Feb'23
May'23
Aug'23
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
33
33
Market Capitalization
2
2
3

Working Capital

USD

•

in mil. unless spec.
Feb'23
May'23
Aug'23
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
13
13
14
Payables & Accruals
10
10
11
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-12.29%
180.32%
29.69%
Free Cash Flow
-244.35%
-501.47%
-43.6%
Net Income, GAAP
10.13%
-7.22%
-43.78%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.04
-0.04
-0.04
-0.07
-0.17
2022
-0.03
-0.03
-0.01
-0.03
-0.09
2023
-0.01
- -
-0.06
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Intellipharmaceutics International Inc. is a pharmaceutical company that specializes in the research, development, and commercialization of novel and generic controlled-release and targeted-release oral solid dosage therapeutics. The company applies its proprietary drug delivery platform technologies—including Hypermatrix, Paradoxical OverDose Resistance and Activation System (PODRAS), and novel Point of Divergence Drug Delivery System (nPODDDS)—to develop abuse-deterrent, sustained-release, and delayed-release pharmaceutical products. Its portfolio and development pipeline comprise generic dexmethylphenidate hydrochloride extended-release capsules for the treatment of attention deficit hyperactivity disorder; Aximris XR, an abuse-deterrent extended-release oxycodone hydrochloride formulation for moderate-to-severe pain management; Regabatin XR, an extended-release pregabalin formulation for neuropathic pain and fibromyalgia; generic metformin hydrochloride extended-release formulations for type 2 diabetes; generic quetiapine fumarate extended-release tablets for schizophrenia and bipolar disorder; generic venlafaxine and desvenlafaxine extended-release formulations for major depressive disorder; and extended-release lamotrigine and levetiracetam formulations for epilepsy. In addition to internal drug development, the company provides formulation design, pharmaceutical technology licensing, and co-development services to international pharmaceutical partners, including commercial licensing relationships with entities such as Par Pharmaceutical, Inc. Founded in 1998 and headquartered in Toronto, Ontario, Canada, the company operates primarily through its main operating subsidiary, Intellipharmaceutics Corp. In recent developments, Intellipharmaceutics International Inc. and Intellipharmaceutics Corp. filed an assignment in bankruptcy under Canada's Bankruptcy and Insolvency Act in October 2024, with KPMG Inc. appointed as trustee-in-bankruptcy to oversee estate administration and liquidation proceedings following cease trade orders issued by securities regulators and the migration of its equity shares to the OTC Expert Market under the symbol IPCIQ.